Search Menu Abstract Background.
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Remikiren is an orally active renin inhibitor with established antihypertensive efficacy. As a single dose it induces renal vasodilatation, suggesting specific renal actions.
- Milyen rizst ehet a cukorbeteg
- Orvosi Hetilap, augusztus ( évfolyam, szám) | Arcanum Digitheca
Data on the renal effects of continued treatment by renin inhibition are not available, either in subjects with normal, treatment of proteinuria in diabetes in subjects with impaired renal function. The effect of 8 days of treatment with remikiren mg o.
Összefoglalás Az elmúlt években a fejlett országokhoz hasonlóan hazánkban is rohamosan nőtt a dializált betegek között a diabeteszes betegek száma, ezen belül is a 2-es típusú diabeteszeseké. A 2-es típusú diabetesben azonban a vesekárosodást a cukorbetegségen kívül vagy mellett a hypertonia, az atherosclerosis, a gyakori húgyúti infekciók is létrehozhatják, de nem ritka az egyidejű glomerulonephritisek előfordulása sem.
Remikiren induced a significant peak fall in mean arterial pressure of Continued treatment with remikiren induced a sustained fall in blood pressure, renal vasodilatation, negative sodium balance, and a reduction in glomerular protein leakage. These data are consistent with a renoprotective potential of renin inhibition.
When administered systemically, renin inhibitors reduce blood pressure in healthy volunteers and hypertensive patients more or less similarly to ACEi [ 4—7 ].
The renal haemodynamic actions of renin inhibitors so far have been consistent with a renoprotective potential. Remarkably, in accordance with earlier animal data [ 1516 ], the renal vasodilator response to renin inhibition was reported to exceed the response to ACE inhibition [ 17 ]. As the clinical application of renin inhibitors has been hampered by their low bioavailability, the experience with these compounds during maintenance treatment in man is very limited.
No data are available thus far on the renal effects of continued treatment with remikiren, or on the renal effects of renin treatment of proteinuria in diabetes in patients with renal function impairment and proteinuria.
In the present study, therefore, we report on the renal and systemic effects of continued treatment for 8 days the renin inhibitor remikiren in hypertensive patients with normal renal function, as well as in patients with impaired renal function and proteinuria.
Subjects and methods Patients and protocol Fourteen caucasian patients with mild to moderate hypertension diastolic blood pressure between 90 and mmHg were included. No other clinical relevant target organ damage was allowed.
All subjects gave their informed consent and the study was approved by the Ethical Committee of the Hospital. Median age of the patients was 53 years range 32— The median body mass index at baseline was Histological diagnoses were glomerulosclerosis 3 ; membranous glomerulopathy 2and IgA nephropathy 1. Systolic blood pressure at entry was ±2 mmHg range — and diastolic blood pressure was ±2 mmHg range 90— ; these values were similar for the essential hypertensives and the renal patients.
In the essential hypertensives median albuminuria at entry was In the renal patients nephrotic range proteinuria was present, with a median of All antihypertensives had been withdrawn at least 3 weeks prior to the study, with the exception of one proteinuric patient in whom diuretic treatment was necessary.
The dose of the diuretic was kept constant throughout the protocol.
This patient was excluded from the analysis of electrolyte balance. During hospitalization they received a diet containing 50 mmol sodium, mmol potassium, 60 g protein, and ml fluids daily. During this baseline period, stabilization of blood pressure, proteinuria, and electrolyte excretion was established. Subsequently, remikiren treatment mg orally o. Blood pressure was measured daily between 11 and 12 a.
Renal haemodynamic measurements were performed pretreatment and on the fifth day of remikiren treatment. On the first and the last treatment day timed blood samples were drawn for measurement of plasma renin activity PRAimmunoreactive renin irRand angII. For each hour the mean value was calculated.
Orvosi Hetilap, Bernstein és munkatársai 3 kimutatták, hogy a diabeteszes kóma h.
Urinary protein was measured by the pyrogallol red—molybdate method. This method has a coefficient of variation of During analysis plasma was first separated from plasma proteins by ethanol extraction. The lower limit of detection is 3.
Circulating levels of remikiren were determined by the radioinhibitor assay of Cumin et al. Glomerular filtration 1rate GFR and effective renal plasma flow ERPF were measured as the renal clearances of constantly infused [I]iothalamate and [I]hippuran respectively. Correction for urine collection errors was applied as described previously [ 19 ]. Values are normalized for body surface area.
Data analysis Results are presented as means±SEM. Data sets that are not normally distributed are presented as medians and ranges.
Ugyanakkor azonban még nem történtek kontrollkísérletes, randomizált vizsgálatok annak bizonyítására, hogy a diabetesben gyakori atherosclerosis kialakulásában ezen lipideltérések döntő szerepet játszanak-e, hasonlóan a nem-cukorbeteg egyéneken észleltekhez. Lehetséges továbbá az is, hogy a hyperlipidaemia a DNP progressiójának is rizikófaktora. A microalbuminuria korai felismerése és befolyásolási lehetőségei Az előzőekben elmondottak alapján a microalbuminuria korai felismerésének érdekében ajánlható algoritmust a 2. Ha az átmeneti microalbuminuriához vezető körülményeket 2.
Data on hormonal responses, blood pressure, renal haemodynamics, and electrolyte balance are presented for all patients taken together.
Data on the responses of proteinuria and albuminuria are presented for the renal patients and the essential hypertensives separately. Results The efficacy of remikiren in blocking the RAS, as well as the drug levels, are shown in Figure 1.
- Terheléses vércukor értékek
- Diabetologia Hungarica
- Bertalan Fodor dr. - Google Tudós
- Cukorbetegség 2 fajta kezelés hírek
PRA fell maximally within 30 min after the first dose of remikiren and remained suppressed during the 12 h following. After dosing, a further decrease to almost undetectable levels occurred.
- Diabetic dermopathy legs
- Clinical Demonstrations – University of Veterinary Medicine Budapest
- Klinikai vizsgálat a Gestational Diabetes Mellitus - Klinikai vizsgálatok nyilvántartása - ICH GCP
- Cukorbetegség szövődményei?trackid=sp-006
Remikiren plasma levels reached their peak within 30 min after oral administration both on the first median Cmax Remikiren was rapidly cleared from the plasma thereafter. It shows that MAP fell significantly, from ±2 to 96±2 mmHg.
The effect on diurnal blood pressure profile is given in Figure 3.